Clinical trial

Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer (mBC) Patients,

NCT06762483

Drugs and interventions used in this trial

0 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

No interventions are currently published for this study in CureCurrent. View the original registry record below.

Study at a glance

Registry-backed

Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer (mBC) Patients,

Design: OBSERVATIONAL · Status: RECRUITING · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeOBSERVATIONAL

Start date2024-12-20

PhaseN/A

Conditions

Breast Cancer, Metastaticunresolved

Interventions

Sponsors & collaborators

European Institute of Oncologylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06762483 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.